Immunis, Inc., a private biotech company and frontrunner in developing cellular secretome therapies for age and disease-related immune decline, has released an animation to explore the potential benefits of immunomodulatory secretome therapies. Secretomes are an emerging class of therapeutics derived from secreted cellular factors including proteins, lipids, nucleic acids, growth factors, and much more.

The secretome provides essential communication and stimulation between cells when resolving an infection, combating a disease, and alleviating cellular damage. A well-functioning immune system is necessary to maintain our health, but aging results in a time-dependent accumulation of molecular and cellular damage to our body, including immune cells, which causes an imbalance of inflammatory and anti-inflammatory responses. Secretomes can influence and refine these immune cell responses, thereby drastically improving how the aging body copes with disease. Check out Immunis’ article called “The Secretome to Longevity” for more details.

Immunis is creating novel secretomes to mitigate the effects of several age-related diseases including sarcopenia. Preclinical data of the investigational secretome, IMMUNA, demonstrated immunomodulatory and regenerative capabilities in aged muscle. IMMUNA is currently being tested in a Phase 1/2a clinical trial to assess safety and tolerability in elderly patients with muscle atrophy associated with knee osteoarthritis, an inflammatory disease that is a leading cause of disability in elderly adults.

The goal is to increase awareness of Immunis’ innovative secretome therapies and showcase how secretomes can be used as tools in regenerative medicine to combat age-related diseases. This video and other scientific content can be viewed on Immunis’ website under the “Media” page.

About Immunis Inc.

Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The investigational product line leverages Immunis’ leading-edge capabilities in secretome technology to deliver a product of all natural, all human immune modulators in their natural relative physiological concentrations. For additional information about Immunis’ Phase 1/2a clinical trial please visit: https://immunisbiomedical.com/clinical-trials/

Cautionary Note Regarding Forward-Looking Statements

This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.